Douglas Gladstone

Associate Professor

19992019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1999 2019

Filter
Letter
2019

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

Strati, P., Fanale, M. A., Oki, Y., Turturro, F., Fayad, L. E., Bartlett, N. L., Gladstone, D., Kasamon, Y. L., Portlock, C. S., Wilson, W. H., Goy, A., Younes, A. & Lee, H. J., Feb 1 2019, In : Haematologica. 104, 2, p. e65-e67

Research output: Contribution to journalLetter

Hodgkin Disease
Rituximab
Hodgkin Disease
Bone Marrow
Transplants
Rituximab
Hashimoto's encephalitis
Acute Promyelocytic Leukemia
Fibrinogen
Heparin
Hemorrhage